<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Van Cutsem, Eric</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CORRECT Trial of Regorafenib in Metastatic Colorectal Cancer: Overall Survival Update</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">There is a significant unmet clinical need for treatment options for metastatic colorectal cancer (mCRC). This article presents updated overall survival (OS) data from the Patients with Metastatic Colorectal Cancer Treated with Regorafenib or Placebo After Failure of Standard Therapy [CORRECT; NCT01103323] trial. The study demonstrated increased survival benefits following regorafenib treatment in patients with previously treated mCRC.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>